Autoimmune diseases have specific pathophysiologic mechanisms leading to an increased risk of arterial and venous thrombosis. The risk of venous thromboembolism (VTE) varies according to the type and stage of the disease, and to concomitant treatments. In this review, we revise the most common autoimmune disease such as antiphospholipid syndrome, inflammatory myositis, polymyositis and dermatomyositis, rheumatoid arthritis, sarcoidosis, Sjogren syndrome, autoimmune haemolytic anaemia, systemic lupus erythematosus, systemic sclerosis, vasculitis and inflammatory bowel disease. We also provide an overview of pathophysiology responsible for the risk of VTE in each autoimmune disorder, and report current indications to anticoagulant treatment for primary and secondary prevention of VTE.
Risk of venous thromboembolism in autoimmune diseases. A comprehensive review / Menichelli, Danilo; Cormaci, Vito Maria; Marucci, Silvia; Franchino, Giovanni; Del Sole, Francesco; Capozza, Alessandro; Fallarino, Alessia; Valeriani, Emanuele; Violi, Francesco; Pignatelli, Pasquale; Pastori, Daniele. - In: AUTOIMMUNITY REVIEWS. - ISSN 1873-0183. - 22:11(2023). [10.1016/j.autrev.2023.103447]
Risk of venous thromboembolism in autoimmune diseases. A comprehensive review
Menichelli, Danilo;Cormaci, Vito Maria;Marucci, Silvia;Franchino, Giovanni;Del Sole, Francesco;Capozza, Alessandro;Fallarino, Alessia;Valeriani, Emanuele;Violi, Francesco;Pignatelli, Pasquale;Pastori, Daniele
2023
Abstract
Autoimmune diseases have specific pathophysiologic mechanisms leading to an increased risk of arterial and venous thrombosis. The risk of venous thromboembolism (VTE) varies according to the type and stage of the disease, and to concomitant treatments. In this review, we revise the most common autoimmune disease such as antiphospholipid syndrome, inflammatory myositis, polymyositis and dermatomyositis, rheumatoid arthritis, sarcoidosis, Sjogren syndrome, autoimmune haemolytic anaemia, systemic lupus erythematosus, systemic sclerosis, vasculitis and inflammatory bowel disease. We also provide an overview of pathophysiology responsible for the risk of VTE in each autoimmune disorder, and report current indications to anticoagulant treatment for primary and secondary prevention of VTE.File | Dimensione | Formato | |
---|---|---|---|
Menichelli_Risk_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.9 MB
Formato
Adobe PDF
|
2.9 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.